Karyopharm Therapeutics Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period endedJune 30,2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromtoCommission file number:001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) 26-3931704(I.R.S. EmployerIdentification Number) (617)658-0600(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☒Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of August 6, 2025, there were8,671,278shares of Common Stock, $0.0001 par value per share, outstanding. TABLE OFCONTENTS PART I-FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements (Unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations3Condensed Consolidated Statements of Comprehensive Income (Loss)4Condensed Consolidated Statements of Cash Flows5Condensed Consolidated Statements of Stockholders’ Deficit6Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29 PART II-OTHER INFORMATION Item 1A.Risk FactorsItem 5.Other InformationItem 6.ExhibitsSignatures KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED BALANCE SHEETS(unaudited)(in thousands, except per share amounts) KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts) Table of Contents KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)(in thousands) KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT(unaudited)(in thousands) KARYOPHARM THERAPEUTICS INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Nature of Business, Basis of Presentation and Segment Information Nature of Business Karyopharm Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the “Company,” “we,” “us,” or“our”), is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery,development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. We wereincorporated in Delaware on December 22, 2008 and have a principal place of business in Newton, Massachusetts. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleusand the cytoplasm. We have discovered and are developing and commercializing novel, small molecule Selective Inhibitor ofNuclear Export compounds that inhibit the nuclear export protein exportin 1. Our primary focus is on marketingXPOVIO®(selinexor) in its currently approved indications, as well as developing and seeking the regulatory approval of selinexoras an oral agent targeting multiple high unmet cancer indications, including our lead clinical programs in myelofibrosis and ourother late-stage clinical programs in endometrial cancer and multiple myeloma. Our lead asset, XPOVIO, received its initial U.S. approval from the U.S. Food and Drug Administration in July 2019 and iscurrently approved and marketed for the following indications: (i) in combination with bortezomib and dexamethasone for thetreatment of adult patients with multiple myeloma who